Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers in Singapore and beyond, and why Asian representation in clinical trials is of vital importance moving forward.
Technology has been a huge enabler in democratising access to quality healthcare, and the beauty of it, especially for mobile technologies, is that technology is everywhere. It is not a unique feature of developed countries.
